Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice

Circulation

Volumn 96, Issue 12, 1997, Pages 4380-4384

  Edwards, Michael H ^a,d   Pierangeli, Silvia ^c   Liu, Xiaowei ^c   Barker, John H ^b   Anderson, Gary ^b   Nigel Harris, E ^c  

^a Division of Rheumatology   (United States)

^b Department of Surgery ^*  (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

^d University of Louisville School of Medicine   (United States)

Author keywords

Antibodies; Anticoagulants; Drugs; Hydroxychloroquine; Thrombus

Indexed keywords

HYDROXYCHLOROQUINE SULFATE; IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMORAL VEIN; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOGENESIS; VEIN THROMBOSIS;

EID: 0031442025     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.12.4380     Document Type: Article

References (33)

1. Harris EN. Syndrome of the Black Swan. Br J Rheumatol 1987;26: 324-326.
2. Rosove MH, Brewer P. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303-308.
3. Derksen RHMV, deGroot PO, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long-term anticoagulant treatment. Ann Rheum Dis. 1993; 52:689-692.
4. Khamashta MA, Cuadrado MJ, Nujic F, Taub NA, Hunt BM, Hughes GRV. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med. 1995;332:993-997.
5. Carter A, Eban R. Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate. Br Med J. 1974;3:94-95.
6. Johnson R, Green J, Charnley J. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop. 1977;127:123-132.
7. Knisely M, Bloch E. Microscopic observations of intravascular agglutination of red cells and consequent sludging of blood in human diseases. Anat Rec. 1942;82:426.
8. Madow B. Use of antimalarial drugs as "desludging' agents in vascular disease processes. JAMA. 1960;172:1630-1633.
9. Petri M, Hochberg M, Hellmann D, Bell W, Goldman D. Incidence of and predictors of thrombotic events in SLE: protective role of hydroxychloroquine. Arthritis Rheum. 1992:35(suppl 9):S54. Abstract.
10. Wallace D. Does hydroxychloroquine sulphate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum. 1987;30: 1435-1436. Letter.
11. Wallace D, Linker-Israeli M, Metzger A, Stecher V. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines un SLE. Lupus. 1993;2(suppl 1):S13-15.
12. Pierangeli SS, Liu XW, Barker JH, Anderson G, Harris EN. Induction if thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost. 1995;74:1361-1367.
13. 2iglycoprotein-1 and human IgG antiphospholipid antibodies. Circulation. 1996;94:1746-1751.
14. Olee T, Pierangeli SS, Handley HH, Novotny W, En J, Harris EN, Woods L, Chen PP. Generation and characterization of monoclonal IgG anticardiolipin antibodies from a patient with the antiphospholipid syndrome. Proc Natl Acad Sci U S A. 1996;93: 8606-8611.
15. Weir DM. Handbook of Experimental Immunology. Oxford, UK: Blackwell Scientific Publishers; 1986.
16. Miller D, Khalil S, Nygard G. Steady state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients. Ann Pharmacother. 1991;25:1302-1305.
17. Harris EN. Annotation: antiphospholipid antibodies. Br J Haematol. 1990;74:1-9.
18. Stockmans F, Deckmyn H, Gruwez J, Vermylen J, Acland R. Continuous quantitative monitoring of mural thrombus kinetics in the crushed rat femoral vein. Thromb Haemost. 1991;65:425-431.
19. Tett S. Clinical pharmacokinetics of slow acting antirheumatic drugs. Clin Phamacokinet. 1993;25:392-407.
20. French J, Hurst N, O'Donnell M, Betts W. Uptake of chloroquine and hydroxychloroquine by human blood leukocytes in vitro: relation to cellular concentrations during antirheumatic therapy. Ann Rheum Dis. 1987;46:42-45.
21. Johnson R. Orth MC, Charnley J. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthop. 1979;144:174-177.
22. Cooke E, Dawson M, Ibbotson R, Bowcock S, Ainsworth M, Pilcher M. Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. J Bone Joint Surg Br. 1977;59-A:496-500.
23. Bertrand E, Cloitre B. Ticolet R, Bile R, Gautier C, Abiyou G, Bohui Y. Antiaggregation action of chloroquine. Med Trop (Mars). 1990;50:143-146.
24. Janicinova V, Nosal R, Petrikova M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res. 1994;74:495-504.
25. Nasal R, Jancinova V, Petrikova M. Choloroquine inhibits stimulated platelets at the arachidonic acid pathway. Thromb Res, 1995; 77:531-542.
26. Billah M, Lapetina E, Cuetracasas P. Phospholipase A2 activity specific for phosphatidic acid. J Biol Chem. 1981;256:5399-5403.
27. McCrea J, Robinson P, Gerrard J. Mepacrine (quinacrine) inhibition of thrombin-induccd platelet responses can be overcome by lysophosphatidic acid. Biochim Biophys Acta. 1985;842:189-194.
28. Cecchi E, Ferraris D. Desludging action of hydroxychloroquine in rheumatoid arthritis. Acta Med Scand. 1962:8:214-221.
29. Bird H, Harkness J, Wright V. Some Theological properties of blood during antirheumatoid therapy. Pharmatherapeutica. 1981;3: 36-39.
30. Ernst E, Rose M, Lee R. Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug's antithrombotic effect. Pharmatherapeutica. 1984; 4:48-52.
31. Fox R. Scripps Clinic and Research Foundation. Lupus. 1996; 5(suppl 1):S4-S10.
32. Khamashta MA, Harris EN, Gharavi AE, Derue G, Hughes GRV. Immune mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis. 1988; 47:849-854.
33. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost. 1995;73:529-534.